NLRP3 inflammasome inhibitors (University of Manchester/Medical Research Council Technology)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameNLRP3 inflammasome inhibitors (University of Manchester/Medical Research Council Technology)
Drug Alias NameNLRP3 inflammasome inhibitors (University of Manchester)NBC-6
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitors
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsDiabetes Mellitus, Type 2Alzheimer DiseaseGout
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Manchester
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlzheimer'S Research UkLifearcEli Lilly And Company +[7] 
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Alzheimer DiseaseGout

Other Information

ATC CodeN/A
Related LinksN/A